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ABSTRACT
Analysis of data on the incidence of typhoid fever and the costs of vaccination of travellers to the
developing world indicates that vaccination may not be cost-effective for travel to countries with a
moderate-to-high endemicity. It may be reasonable to selectively vaccinate travellers to countries with a
very high incidence of typhoid fever, and particularly those who are visiting relatives or who will be in
close contact with the local population. Vaccination of travellers on standard tourist itineraries is
probably not necessary. The basic preventative measure for typhoid fever should be the avoidance of
potentially contaminated food and drink.
Keywords Cost-effectiveness, Salmonella enterica serovar Typhi, typhoid fever, vaccination
Clin Microbiol Infect 2004; 10: 681–683
Typhoid fever is a systemic infection caused by
Salmonella enterica serovar Typhi that is acquired
by ingestion of contaminated food or water [1].
Humans comprise the only known reservoir of
this bacillus. Typhoid fever is uncommon in
industrialised regions such as the USA, Canada,
Europe, Australia and Japan (which are all
regions with low endemicity), but is still common
in developing countries. The disease affects c. 16
million persons ⁄year worldwide, most of whom
reside in developing countries [2]. The result is
that new cases of typhoid fever in industrialised
countries are related increasingly to travel to
developing countries. For example, in the USA,
the number of cases of typhoid fever reported
annually has remained relatively stable at about
450, but the proportion of travel-related cases
increased from 33% in 1967–1972 to 62% in 1975–
1984, and to 72% in 1985–1994 [3–5]. Based on
such data, the public health authorities in most
industrialised countries recommend vaccination
against typhoid fever for travellers to the devel-
oping world (i.e., countries in Asia, Africa, and
Central and South America) [6–8].
Three typhoid fever vaccines are available
currently: (1) a parenteral heat–phenol-inacti-
vated whole-cell vaccine (although this is not
used widely because of its high toxicity); (2) an
oral live-attenuated vaccine manufactured from
the Ty21a strain of S. enterica Typhi; and (3) the
purified capsular polysaccharide parenteral vac-
cine Vi [9–14]. However, the protective efficacy
(51–73%) of these three vaccines, which was
evaluated in populations living in endemic areas
and not in travellers to foreign countries, is
unsatisfactory [15–18]. In addition, data regarding
the cost-effectiveness of these vaccines are scarce.
Two reports have suggested that immunisation
against typhoid fever of all travellers to the
developing world is not cost-beneficial [12,14].
In order to examine the issue of cost-effective-
ness, we collated data regarding the incidence of
typhoid fever in travellers from the USA to the
developing world in the period 1974–1994 [3–5].
Relevant information was collected from the list
of cases of reportable disease published in Mor-
bidity and Mortality Weekly Reports (MMWR) by
the Centers for Disease Control and Prevention
(Atlanta, GA, USA), and typhoid fever case report
forms submitted by state and local health depart-
ments. Data on the efficacy and toxicity of typhoid
fever vaccines (parenteral whole cell, oral Ty21a,
and parenteral Vi) were obtained from a
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meta-analysis of 17 efficacy trials and 20 toxicity
studies [15]. These trials examined the efficacy of
vaccines in people living in endemic areas only,
and not in travellers. Subsequently, data from
these studies were extrapolated to travellers,
although this is an unproved assumption. Data
regarding the costs of the vaccines were obtained
from the unit costs published in the UK [19]. Data
were analysed for the two vaccines that are
currently used widely, namely the oral Ty21a
and parenteral Vi vaccines, and not for the
parenteral whole-cell vaccine, which is no longer
used widely because of its high toxicity.
According to this information, the cost of
typhoid fever vaccination was calculated for
travellers in terms of every case prevented. If
the risk of travel-associated typhoid fever in
unimmunised travellers to a particular region is
one case ⁄n persons travelling, the sum of travel-
lers that must be immunised to prevent one case
of typhoid fever is n ‚ the efficacy of the vaccine
used. So, the cost for every case prevented is the
sum of vaccination (n ‚ efficacy) · unit cost of the
vaccine.
Table 1 summarises the available epidemiolog-
ical data on the incidence of typhoid fever in
international travellers visiting various countries
during the period 1974–1994. Based on these data,
the countries were classified into three subgroups
according to the incidence of typhoid fever: (1)
countries with a moderate endemicity of typhoid
fever (Middle East), with about ten cases ⁄million
travellers; (2) countries with a high endemicity
(Central America, South America, North Africa,
South Africa and Southeast Asia), with about 20
cases ⁄million travellers; and (3) countries with a
very high endemicity (Indian subcontinent, and
probably countries of Central Africa for which
there are no good epidemiological data), with
about 200 cases ⁄million travellers.
According to the meta-analysis of Engels et al.
[15], the efficacy of two doses of parenteral whole-
cell vaccine is 73% (95% CI, 65–80%), that of
three doses of oral Ty21a vaccine is 51% (95% CI,
35–63%), and that of one dose of parenteral Vi
vaccine is 55% (95% CI, 30–71%). The whole-cell
vaccine is associated more frequently with
adverse events (mainly fever and local reactions)
and was not considered further in the present
analysis. The unit cost for oral Ty21a vaccine
(Vivotif) is Euro 21, and that of Vi vaccine
(Typhim Vi) is Euro 15. Table 2 lists the corres-
ponding calculated costs for each case of typhoid
fever prevented among travellers to each of the
country subgroups.
According to this analysis, vaccination
against typhoid fever for travellers is probably
Table 1. Incidence of typhoid fever ⁄
million travellers for each country
visitedArea visited
Number of cases of typhoid fever/106 travellers
1977–1979 [5] 1974–1975 [14] 1980–1990 [3] 1985–1994 [4]
Americas
Mexico 29–34 20.2 11 1–2
Central America 6.5–13 8.5 ND 5–21
Haiti 29 41.8 35 ND
Jamaica 10 4.9 ND ND
Other Caribbean countries 0.7 2.0 5.3 < 1–3
Chile ND 58.4 ND ND
Peru ND 173.8 500.7 ND
Other South America 8–24 13.2 12.7 2
Asia
India 318–415 118.5 80 110–1117
Pakistan 481 105.1 ND ND
Iran 130 ND ND ND
Other Near Eastern 14.4 9.4 ND < 1–2
Far East and Pacific 6.5 4.8 43.8 5–12
Africa 44.5–72 10.2 ND 4–28
Egypt ND 11.3 ND ND
North Africa 94 ND ND ND
Sub-Saharan Africa 12.3 7.2 ND ND
Europe 1.5–2.5 0.7 ND < 1
ND, no data.
Table 2. Cost of a typhoid fever vaccination programme
in travellers for every case of typhoid fever prevented
Subgroups of developing countries
Cost of vaccination/case of
typhoid fever prevented
Ty21a Vi
Countries with moderate endemicity
(c. 10 cases ⁄ million travellers)
Euro 4076 Euro 2718
Countries with high endemicity
(c. 20 cases ⁄ million travellers)
Euro 2038 Euro 1359
Countries with very high endemicity
(c. 200 cases ⁄ million travellers)
Euro 204 Euro 136
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not cost-effective in countries with moderate or
high endemicity. From the public health point of
view, the cost figures in Table 2 are high com-
pared to other usually non-funded health care
needs. It seems more reasonable to selectively
vaccinate travellers to countries with a very high
endemicity of typhoid fever, and those at high
risk because of special circumstances. Travellers
who are visiting relatives, or who will be in close
contact with the local population, need to be
immunised. In contrast, the vaccination of travel-
lers on standard tourist itineraries is probably not
necessary [14,20,21].
The above analysis is not without its limita-
tions. The most important is the fact that none of
the efficacy trials examined the travelling popu-
lation; rather, they examined the population
living in endemic areas, whose baseline immunity
probably differs from that of travellers. Therefore,
the extrapolation of the results can be questioned,
and further research is needed to clarify the
efficacy and cost-effectiveness of typhoid fever
vaccination programmes in travellers [22]. Nev-
ertheless, guidelines for preventing typhoid fever
in travellers should be clarified. Specifically, it
should be stressed that vaccination against
typhoid fever is not the main preventative meas-
ure. Indeed, avoidance of potentially contamin-
ated food and drink should be the basic advice
given to travellers, because the ingestion of a large
inoculum of S. enterica Typhi may result in
infection despite immunisation.
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